Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:39 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 9,942 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
San Diego, California • Jacksonville, Florida • Sweetwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional

A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

NCT00001992
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional Results available

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

NCT00671671
View directory record Official record
Conditions
Hepatitis, Chronic, Hepatitis C Virus
Interventions
Small Molecule Agent (PF-868554)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Nov 3, 2026, 1:39 PM EST
Completed No phase listed Observational

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

NCT00923832
View directory record Official record
Conditions
Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 1:39 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Acute Respiratory Infection Consortium

NCT01021098
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
17 Years to 55 Years
Enrollment
2,018 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
5
States / cities
San Diego, California • Bethesda, Maryland • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Nov 3, 2026, 1:39 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

NCT01732198
View directory record Official record
Conditions
Infectious Disease
Interventions
NU300, ActHIB, Prevnar 13
Biological
Lead sponsor
Nuron Biotech Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oakland, California • Bardstown, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Nov 3, 2026, 1:39 PM EST
Completed Not applicable Interventional

AWAITS: A Web-based E-health Application for Active Illicit Opioid Users

NCT03402672
View directory record Official record
Conditions
Opioid-use Disorder, IV Drug Usage, Overdose, Drug Addiction, Substance Use Disorders
Interventions
self-administered, e-health application
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 2Phase 3 Interventional

The Use of Prophylactic Antibiotics In the Management of Dog Bites

NCT00185939
View directory record Official record
Conditions
Bite, Wound, Infection
Interventions
Augmentin
Drug
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Burlingame, California • San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2006 · Synced Nov 3, 2026, 1:39 PM EST
Not listed Phase 4 Interventional

Gentamicin Bladder Instillation Trial

NCT01884467
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Placebo
Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

NCT00574600
View directory record Official record
Conditions
HIV Infections
Interventions
SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Nov 3, 2026, 1:39 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

NCT06187064
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea, Syphilis, Trichomonas
Interventions
Mobile Van Clinic
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 1:39 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

NCT01321502
View directory record Official record
Conditions
Herpes
Interventions
famciclovir
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 3, 2026, 1:39 PM EST
Recruiting Phase 4 Interventional

Placement of Antibiotic Powder in Wounds During the Emergency Room

NCT03765567
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 3, 2026, 1:39 PM EST
Completed Not applicable Interventional

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Nov 3, 2026, 1:39 PM EST
Recruiting Not applicable Interventional

Project neuroARTEMIS

NCT06814275
View directory record Official record
Conditions
Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
Interventions
ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 59 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional

A Phase I Study of Methotrexate for HIV Infection

NCT00000834
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Methotrexate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001037
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
2
States / cities
St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 1:39 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
AviClear Lase Treatment, Sham (No Treatment)
Device
Lead sponsor
Wynn Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rosemead, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 3, 2026, 1:39 PM EST
Recruiting Phase 3 Interventional

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

NCT07020819
View directory record Official record
Conditions
Guillain-Barre Syndrome
Interventions
Tanruprubart
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
8 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 3, 2026, 1:39 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Chlorhexidine Cleansing on Bacteria Colonizing the Umbilical Cord of Infants in Bangladesh

NCT00719329
View directory record Official record
Conditions
Infection
Interventions
Chlorhexidine 4.0%, Dry Cord Care
Drug · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Up to 7 Days
Enrollment
1,931 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Nov 3, 2026, 1:39 PM EST
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Nov 3, 2026, 1:39 PM EST